What are the characteristics of EXOSENS stock?

EXOSENS is a company operating in the Défense sector. The stock is listed on Euronext Paris under ISIN FR001400Q9V2.

What is the recent price evolution of EXOSENS stock?

Since last close: -1.43 %. Over one week: -7.69 %. Over one year: 24.46 %.

Exosens Launches PhaseStudio, an Optical Wavefront Measurement Software

On Wednesday, Exosens announced the launch of PhaseStudio, a software developed over four years aimed at revolutionizing wavefront measurement in optical metrology. This technological advancement highlights the company's commitment to innovation in optical metrology applications.

Published on Jun 24, 2026 at 14:02

EXOSENS

55.20 € -1.43 %

Add us as a preferred source on Google

A Software Resulting from Four Years of Development

PhaseStudio represents a significant breakthrough in the field of wavefront measurement and metrology solutions, according to Exosens. The software was developed over a period of four years, reflecting the group's commitment to technological innovation in optical diagnostic and advanced imaging applications.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

🏢 Other stocks — Défense

🗞️ Safran Share: Nearly 3% Decline, Among CAC 40's Steepest Falls This Morning 🗞️ Biman Bangladesh Airlines Orders Ten Airbus Aircraft, Including Four A350s, to Target North America 🗞️ Over one year, Thales shares drop more than 17% and continue their decline during the session 🗞️ Space Defense: Dassault Aviation Presents Advances of its Vortex Space Aircraft

Context

Period

Period: S1 2026

Key reported figures

Revenue: 253,1 millions d'euros
Quarterly revenue: 253,1 millions d'euros
EBITDA: 50,9 millions d'euros
EBITDA margin: 31,2 %
Net income: 15,3 millions d'euros
Free cash flow: 31,4 millions d'euros
199,8 millions d'euros

Guidance from the release

Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle

Risks mentioned

Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)

Opportunities identified

Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques

Outlook / guidance

Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

A Software Resulting from Four Years of Development

Context

Also read